Advertisement

The ASCO Post Newsreels help clinicians stay up to date on news in the world of clinical oncology and hematology. Newsreels feature leading authorities presenting high-impact clinical findings at major oncology meetings throughout the year.



Showing All Recent Newsreels Videos


Advertisement

EHA 2021 Virtual Congress

Efstathios Kastritis, MD, on Amyloidosis: Standard of Care Plus Daratumumab

Keith W. Pratz, MD, on AML: Venetoclax, Azacitidine, and Disease Response

Arnon P. Kater, MD, PhD, on CLL: Fixed-Duration Ibrutinib and Venetoclax vs Chlorambucil Plus Obinutuzumab


2021 ASCO Annual Meeting

Jingxuan Zhao, MPH, on How Medicaid Expansion Affects Long-Term Cancer Survival

Heather A. Wakelee, MD, on NSCLC: Atezolizumab vs Best Supportive Care After Chemotherapy

Narjust Duma, MD, and Gladys I. Rodriguez, MD, on A First for Hispanic Women: Formation of a YIA for Latinas

Evan J. Lipson, MD, on Melanoma: Relatlimab and Nivolumab in First-Line Treatment of Advanced Disease

Andrew Tutt, PhD, MBChB, on Breast Cancer: Olaparib After Chemotherapy in Germline BRCA1/2–Mutated Tumors

Toni K. Choueiri, MD, on Renal Cell Carcinoma: Pembrolizumab vs Placebo in Adjuvant Treatment

Ian Chau, MD, on Esophageal Squamous Cell Carcinoma: Nivolumab, Ipilimumab, and Chemotherapy for Advanced Disease

Michael J. Morris, MD, on Prostate Cancer: LuPSMA in the Metastatic Setting

Linda R. Mileshkin, MBBS, MD, on Cervical Cancer: Adjuvant Chemotherapy After Chemoradiation

Debora S. Bruno, MD, on NSCLC: Racial Disparities in Biomarker Testing and Clinical Trial Enrollment

Taiga Nishihori, MD, on Multiple Myeloma: Maintenance Ixazomib After Transplant

Pasi A. Janne, MD, PhD, on NSCLC: Patritumab Deruxtecan to Target HER3

Byoung Chul Cho, MD, PhD, on NSCLC: Amivantamab Plus Lazertinib for Treatment of Relapsed Disease

Vamsidhar Velcheti, MD, on NSCLC: Sotorasib in KRAS-Mutated Disease

Brian I. Rini, MD, on RCC: Pembrolizumab Plus Axitinib vs Sunitinib as First-Line Therapy

Massimo Cristofanilli, MD, on Breast Cancer: Updated Analysis on Palbociclib Plus Fulvestrant

Robert J. Motzer, MD, on RCC: Quality of Life for Patients Treated With Lenvatinib-Based Therapy vs Sunitinib

Karim Fizazi, MD, PhD, on Prostate Cancer: Abiraterone Acetate, Prednisone, and Radiotherapy in Metastatic Disease

Ingrid A. Mayer, MD, on Triple-Negative Breast Cancer: Platinum-Based Chemotherapy vs Capecitabine

Nadia Harbeck, MD, PhD, on Early Breast Cancer: Benefit of a De-escalated Regimen

Thierry André, MD, on Pembrolizumab vs Chemotherapy in MSI-High Colorectal Cancer

Cathy Eng, MD, on Colorectal Cancer: FOLFOXIRI, Cetuximab, and Bevacizumab as First-Line Treatment

Sumanta K. Pal, MD, on Urothelial Carcinoma: Comparing Cisplatin and Gemcitabine With or Without Berzosertib

Nadia Harbeck, MD, PhD, on Luminal Breast Cancer: Prognostic Impact of Recurrence Score, Endocrine Response, and Other Factors

Ann S. LaCasce, MD, on Hodgkin Lymphoma: PET-Adapted Therapy for Bulky Disease

Nicholas J. Short, MD, on ALL: Ponatinib Plus Blinatumomab May Help Patients Avoid Transplants

Geoffrey J. Lindeman, MBBS, PhD, on Breast Cancer: Venetoclax and Fulvestrant in ER-Positive, HER2-Negative Disease

Peter C. Black, MD, on Prostate Cancer Health-Care Disparities: Expert Perspective

Sibylle Loibl, MD, PhD, on Triple-Negative Breast Cancer: Improving Long-Term Outcomes With Durvalumab

Neeraj Agarwal, MD, on Prostate Cancer: Androgen-Deprivation Therapy With Orteronel or Bicalutamide

Matt D. Galsky, MD, on Bladder Cancer: Neoadjuvant Therapy With Gemcitabine, Cisplatin, and Nivolumab

Paolo Ghia, MD, PhD, on CLL/SLL and Ibrutinib Plus Venetoclax: A Primary Analysis of the CAPTIVATE Trial

Brian K. Link, MD, on Mantle Cell Lymphoma: Expert Perspective on Treatments Now and Those to Come

Peter H. O’Donnell, MD, on Urothelial Cancer: First-Line Pembrolizumab in Cisplatin-Ineligible Patients

Priya Rastogi, MD, on Breast Cancer: Predicting the Benefit of Extended Letrozole Therapy

Martin Reck, MD, PhD, on NSCLC: Nivolumab, Ipilimumab, and Chemotherapy for Advanced Disease

Bijal D. Shah, MD, on CLL: CAR T-Cell Therapy With Brexucabtagene Autoleucel

Neeraj Agarwal, MD, on Treatment Patterns and Disparities in Patients With Prostate Cancer


AACR Annual Meeting 2021

Rita Nanda, MD, on Triple-Negative Breast Cancer: Emerging Therapeutic Strategies

Vivek Subbiah, MD, on RET Fusion–Positive Cancers: Efficacy of Selpercatinib

Patrick M. Forde, MD, on NSCLC: Nivolumab and Chemotherapy as Neoadjuvant Treatment

Matthew J. Matasar, MD, on Indolent NHL: New Data on Copanlisib Plus Rituximab

Jessica C. Hassel, MD, on Uveal Melanoma: Comparing Tebentafusp With Standard Therapies

Brian I. Rini, MD, on Renal Cell Carcinoma: Data on Atezolizumab, Bevacizumab, and Sunitinib

Samra Turajlic, MBBS, PhD, on Understanding Metastatic Disease in Renal Cancer and Melanoma

Enrique Grande, MD, PhD, on Urothelial Carcinoma: Treatment With Atezolizumab, Platinum, and Gemcitabine

Carey K. Anders, MD, on Brain Metastases: Integrating Immunotherapy Into Clinical Care

Katelyn T. Byrne, PhD, on the Clinical Impact of T-Cell Inflammation in the Tumor Microenvironment

Dennis J. Slamon, MD, PhD, on Exploiting Cancer Biology in Developing New Treatment Paradigms

Richard S. Finn, MD, on Treating Hepatocellular Carcinoma With Atezolizumab, Bevacizumab, and Sorafenib

Linda T. Vahdat, MD, MBA, on Triple-Negative Breast Cancer: Targeting the Tumor Microenvironment

Joann G. Elmore, MD, MPH, on Cancer Diagnosis: When Pathologists Disagree, Artificial Intelligence May Help

Jeanne Tie, MD, MBChB, on Circulating Tumor DNA, Minimal Residual Disease, and Adjuvant Treatment

Charlotte E. Ariyan, MD, PhD, on Metastasectomy After Immunotherapy: Is It Effective?

Ralph R. Weichselbaum, MD, on Oligometastasis: Biologic Basis and Therapeutic Opportunities

Matthew G. Vander Heiden, MD, PhD, and Karen H. Vousden, PhD: A Conversation About the Role of Diet in Cancer

Michel Sadelain, MD, PhD, on the Road to Synthetic Immunity: Novel CAR Designs

Lipika Goyal, MD, on Treating Intrahepatic Cholangiocarcinoma With Futibatinib

Georgina V. Long, MD, PhD, on Melanoma: Nivolumab Plus Ipilimumab vs Nivolumab Alone


Quick Chats

Heinz-Josef Lenz, MD, and Axel Grothey, MD, on Colorectal Cancer: Molecular Testing and Interpreting an NGS Report

Heinz-Josef Lenz, MD, and Axel Grothey, MD, on Liquid Biopsies for Colorectal and Other GI Cancers

Paul G. Richardson, MD, and Peter M. Voorhees, MD, on Multiple Myeloma: Surveying the Evolving Landscape of Up-Front Drugs

Andrew D. Zelenetz, MD, PhD, and Stephen J. Schuster, MD, on CAR T Cells for Hematologic Malignancies: Where We’re At


SGO 2021 Virtual Annual Meeting on Womens Cancer

Vicky Makker, MD, on Endometrial Cancer: Lenvatinib Plus Pembrolizumab

Rebecca S. Kristeleit, MD, PhD, on Relapsed Ovarian Cancer: Rucaparib vs Chemotherapy

William H. Bradley, MD, on Ovarian Cancer: 5-Year Follow-up on Maintenance Olaparib

Edward L. Trimble, MD, MPH, on Cervical Cancer: A Global WHO Initiative

Brian M. Slomovitz, MD, on the Impact of COVID-19 on Gynecologic Cancer Research

Morcos N. Nakhla, MS, on Surgical Outcomes for Frail Patients With Ovarian Cancer

Ursula A. Matulonis, MD, on Ovarian Cancer: Niraparib as Maintenance Therapy

Shannon N. Westin, MD, on Treating Endometrial Cancer With Enzalutamide, Paclitaxel, and Carboplatin

Hyun C. Chung, MD, on Pembrolizumab for Advanced Cervical Cancer: Update From KEYNOTE-158

Charles N. Landen, MD, on Newly Diagnosed Ovarian Cancer: BRCA Mutations, PD-L1 Expression, and Combination Chemoimmunotherapy

Alice P. Barr, MD, on Advanced Ovarian Cancer: Minimally Invasive vs Open Surgery After Chemotherapy

Sandro Pignata, MD, PhD, on BRCA-Mutated Ovarian Cancer: Maintenance Olaparib Outcomes

Emily Hinchcliff, MD, MPH, on Treating Non–Clear Cell Ovarian Cancer With Durvalumab and Tremelimumab

Lauren Thomaier, MD, on Predicting Chemotherapy-Induced Peripheral Neuropathy in Gynecologic Cancer Survivors

Supriya Chopra, MD, on Cervical Cancer: Reducing Late Effects of Bowel Toxicity

Laura Chambers, DO, on Treating Epithelial Ovarian Cancer With Cisplatin and Paclitaxel During Surgery

Dana M. Roque, MD, on Ovarian, Fallopian Tube, and Peritoneal Cancers: Possible New Therapeutic Option for Heavily Pretreated Disease

Brittany A. Davidson, MD, on a Model to Predict the Need for Opioids After Gynecologic Surgery

Eric Pujade-Lauraine, MD, PhD, on First-Line Maintenance Therapy in Ovarian Cancer

Amir A. Jazaeri, MD, on Metastatic Cervical Cancer: The Role of Immunotherapy

Andreas Obermair, MD, on Treating Endometrial Adenocarcinoma With a Levonorgestrel Intrauterine Device

Anthony B. Costales, MD, on Advanced Ovarian Cancer: Predicting the Benefits of Minimally Invasive Surgery


NCCN 2021 Virtual Annual Conference

Sandy Srinivas, MD, on Managing Metastatic Castration-Resistant Prostate Cancer

Shivan J. Mehta, MD, MBA, on Preventing and Controlling HPV-Associated Cancers

William J. Gradishar, MD, on Triple-Negative Breast Cancer: NCCN Guidelines Update

Robert Winn, MD, on Strategies for Reducing Racial Disparities in Oncology

Arlene O. Siefker-Radtke, MD, on Urothelial Bladder Cancer: New Settings for Immune Checkpoint Inhibitors

Susan M. Swetter, MD, on Molecular Testing for Cutaneous Melanoma

Gabrielle A. Zecha, PA-C, MHA, and Aaron Begue, MS, RN, NP-C, OCN: The Role of Advanced Practice Providers in Oncology Care

Shaji K. Kumar, MD, on Multiple Myeloma: NCCN Guidelines Update

Lori J. Wirth, MD, on Advanced Thyroid Carcinoma: Evolving Systemic Therapy Options

Alexander E. Perl, MD, on Acute Myeloid Leukemia: Treatment Updates

Eric Jonasch, MD, on Hereditary Renal Cell Carcinoma: Screening, Diagnosis, and Management

Mary F. Mulcahy, MD, and Crystal S. Denlinger, MD, on NCCN Guidelines Updates: Gastric and Esophageal Cancers

Thomas K. Varghese, Jr, MD, on the Effects of the COVID-19 Pandemic on Cancer Care

David G. Pfister, MD, on Supportive Care in Head and Neck Cancers: Multidisciplinary Management

April K. Salama, MD, on Managing Melanoma Brain Metastases

Jennifer R. Brown, MD, PhD, on Managing Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Melinda L. Telli, MD, on HER2-Positive Breast Cancer: NCCN Guidelines Update


2021 Genitourinary Cancers Symposium

Christopher Sweeney, MBBS, on Prostate Cancer: Analyzing Biomarkers, Ipatasertib Plus Abiraterone

Thomas Powles, MD, PhD, on Urothelial Carcinoma: Enfortumab Vedotin-ejfv vs Chemotherapy

Toni K. Choueiri, MD, on RCC: Treatment With Lenvatinib Plus Pembrolizumab or Everolimus vs Sunitinib

Daniel M. Geynisman, MD, on Bladder Cancer: Risk-Enabled Treatment After Neoadjuvant Chemotherapy

Monika Joshi, MD, on Urothelial Cancer of the Bladder: Durvalumab and Radiotherapy for Localized Disease

Toni K. Choueiri, MD, on Clear Cell RCC: Treatment With Belzutifan Plus Cabozantinib

Christopher Sweeney, MBBS, and Thomas Powles, MD, PhD, on Treating GU Malignancies: Expert Views

Sumanta K. Pal, MD, on Papillary RCC: Sunitinib vs Cabozantinib, Crizotinib, or Savolitinib in Metastatic Disease

Sumanta K. Pal, MD, on Advanced RCC: Tivozanib to Treat Disease Progression After Axitinib

Neeraj Agarwal, MD, on Prostate Cancer: Apalutamide vs Placebo in Treatment of Metastatic Disease

Felix Y. Feng, MD, on Prostate Cancer: Choosing Patients Who May Benefit From Apalutamide

Elizabeth R. Plimack, MD, on RCC: Outcomes With Pembrolizumab Plus Axitinib

Elizabeth R. Plimack, MD, on Renal Cell Cancer Highlights From the 2021 Genitourinary Cancers Symposium

Elizabeth R. Plimack, MD, on Bladder Cancer Highlights From the 2021 Genitourinary Cancers Symposium

Tracy L. Rose, MD, on Bladder Cancer: Gemcitabine, Cisplatin, and Pembrolizumab as Neoadjuvant Therapy


AACR Virtual Meeting: COVID-19 and Cancer 2021

Toni K. Choueiri, MD, on the Effects of Cancer Treatments on Patients Infected With COVID-19

Antoni Ribas, MD, PhD, on Highlights of AACR’s COVID-19 and Cancer Meeting

Giuseppe Curigliano, MD, PhD: In the Face of COVID, Continuity in Cancer Care

David Fajgenbaum, MD, MBA, on Repurposing Cancer Drugs to Treat COVID-19


IASLC 2020 World Conference on Lung Cancer in Singapore

Giorgio V. Scagliotti, MD, PhD, on Doubling the Lung Cancer Cure Rate by 2025: A Realistic Goal

Dean Fennell, FRCP, PhD, on Mesothelioma: Nivolumab vs Placebo in Relapsed Disease

Silvia Novello, MD, PhD, on NSCLC: Pharmacogenomics-Driven vs Standard Adjuvant Chemotherapy

Prasad S. Adusumilli, MD, on Cell Therapy for Solid Tumors

Fred R. Hirsch, MD, PhD, on Lung Cancer: Survival and Tumor Mutation Burden

Jill Feldman on Diversifying the Criteria for Inclusion in Clinical Trials

Martin Reck, MD, PhD, on NSCLC: Pembrolizumab Plus Ipilimumab in First-Line Treatment

Justin F. Gainor, MD, on NSCLC: Study Results on Nivolumab vs Ipilimumab, Bemcentinib Plus Pembrolizumab

Roy S. Herbst, MD, PhD, on NSCLC: Osimertinib and Patient-Reported Outcomes

Bruce E. Johnson, MD, on Evolving Challenges in Lung Cancer Drug Development

Luis M. Montuenga, PhD, on Noninvasive Biomarkers in Lung Cancer Screening

Jill Feldman: A Determined Cancer Survivor Shares Her Story of a Family Devastated by Lung Cancer

Martin Reck, MD, PhD, on NSCLC: Pembrolizumab, Platinum Chemotherapy, and Radiotherapy in Advanced Disease

Martin Reck, MD, PhD, on SCLC: Maintenance Therapy for Patients With Extensive-Stage Disease

Roy S. Herbst, MD, PhD, on LUNG-MAP, Circulating Tumor DNA, and Tissue Molecular Analysis

Hossein Borghaei, DO, on Bispecific T-Cell–Engager Immune Therapy for Small Cell Lung Cancer

Fred R. Hirsch, MD, PhD, on Searching for Therapeutic Strategies for Patients With Lung Cancer and COVID-19 Infection


Special Messages

Julie Gralow, MD, on Goals as ASCO CMO

Karen E. Knudsen, MBA, PhD: The American Cancer Society’s First Female CEO Speaks Out

John Marshall, MD, and Liza Marshall: When Cancer Strikes an Oncologist’s Family


2021 Gastrointestinal Cancers Symposium

Zev A. Wainberg, MD, on Gastric/Gastroesophageal Junction Adenocarcinoma: Bemarituzumab and FOLFOX

Wasat Mansoor, MBChB, PhD, on Esophageal Cancer: Quality of Life With Pembrolizumab and Chemotherapy

Afsaneh Barzi, MD, PhD, on Disparities in Access to Screening and Treatment of GI Cancers

Rutika Mehta, MD, MPH, on Gastric Cancer: Adjuvant Chemotherapy With S-1 and Docetaxel

Romain Cohen, MD, PhD, on Colon Cancer: Prognostic Value of Tumor Deposits

Kai-Keen Shiu, MD, PhD, on Colorectal Cancer: Pembrolizumab vs Chemotherapy for Microsatellite Instability–High Disease

Milind M. Javle, MD, on Cholangiocarcinoma: Treatment With Infigratinib

Tenna V. Henriksen, PhD Candidate, on Colorectal Cancer: Circulating Tumor DNA Analysis to Improve Treatment

Richard S. Finn, MD, on HCC: Atezolizumab Plus Bevacizumab vs Sorafenib

Talia Golan, MD, on Pancreatic Cancer: Olaparib for BRCA-Mutated Disease

Matthew H.G. Katz, MD, on Pancreatic Cancer: Preoperative mFOLFIRINOX for Resectable Disease

Andrew X. Zhu, MD, PhD, on IDH1-Mutant Cholangiocarcinoma: Ivosidenib vs Placebo

Thierry André, MD, on Mismatch Repair–Deficient Solid Cancers: Safety and Efficacy of Dostarlimab

Rocio Garcia-Carbonero, MD, on Treating Neuroendocrine Tumors of Nonpancreatic Origin With Octreotide Acetate and Axitinib


2020 San Antonio Breast Cancer Symposium

Chirag Shah, MD, on Assessing DCIS Recurrence Risk

Debra A. Pratt, MD, on Time to Completion of Breast Cancer Treatment and Survival

Nadia Harbeck, MD, on Early Breast Cancer: Endocrine Therapy After Preoperative Treatment

Joseph A. Sparano, MD, on HR+, HER2– Breast Cancer: Individualizing Prognosis and Predicting Treatment Success

Patricia A. Ganz, MD, on Younger Breast Cancer Survivors: Managing Depression

Sara A. Hurvitz, MD, on Triple-Negative Breast Cancer: Sacituzumab Govitecan and Chemotherapy

Lee S. Schwartzberg, MD, on HER2– HR+ Breast Cancer: Tesetaxel and Capecitabine

Roisin M. Connolly, MD, on HR+ Advanced Breast Cancer: Endocrine Therapy and Entinostat

Joyce V. Lee, PhD, on Triple-Negative Breast Cancer: MYC as a Predictor of Treatment Response

Sibylle Loibl, MD, on HR+ HER2– Primary Breast Cancer: Palbociclib and Endocrine Therapy

Elizabeth A. Mittendorf, MD, PhD, on Her Plenary Lecture: Local Regional Management Following Neoadjuvant Therapy

Ann H. Partridge, MD, MPH, on ER+, HER2– Breast Cancer: More Effective Treatments Needed


2020 ASH Annual Meeting & Exposition

Ann-Kathrin Eisfeld, MD, on AML in Black Patients: Racial Disparities in Survival Outcomes

Corey Cutler, MD, MPH, on MDS: Evaluating Treatments in Older Patients With Advanced Disease

Emmanuel Bachy, MD, PhD, on Peripheral T-Cell Lymphoma: Romidepsin Plus CHOP

Radhika Gangaraju, MD, and Smita Bhatia, MD, MPH, on Coronary Heart Disease Risk in Blood or Marrow Transplant Survivors

Curtis Lachowiez, MD, on AML: Venetoclax in Combination With Standard Intensive Induction/Consolidation Therapy

Sagar Lonial, MD, on CAR T-Cell Therapies for Myeloma: Novel Approaches and Longer-Term Follow-up Data

Jyoti Nangalia, MBBChir, on MPN: A New Paradigm for the Development of Blood Cancer?

David T. Teachey, MD, on Pediatric Leukemia and Lymphoma: New Findings on Cranial Radiation and Bortezomib

Paul G. Richardson, MD, on Multiple Myeloma: Roundup of Three Key Studies

Matthew S. Davids, MD, on CLL/SLL: New Data on Ibrutinib, Venetoclax, and Rituximab Therapies

Caron A. Jacobson, MD, on Treating Large B-Cell Lymphoma With Axicabtagene Ciloleucel

Ari M. Melnick, MD, on Activated B-Cell­–Like DLBCL: Gain-of-Function Mutations and Resistance to Ibrutinib

Meletios A. Dimopoulos, MD, on Multiple Myeloma: Daratumumab, Pomalidomide, and Dexamethasone

Andrew D. Zelenetz, MD, PhD, on Mantle Cell Lymphoma: Immunochemotherapy Plus Lenalidomide

Andrew D. Zelenetz, MD, PhD, on Mantle Cell Lymphoma: Expert Perspective on Key Clinical Trials

Hassan Awada, MD, on AML and Machine Learning: Improving Prognostication

Jorge E. Cortes, MD, on CML: Expert Perspective on Key ASH Abstracts

Farhad Ravandi, MD, on AML: Novel Combination Therapies for Newly Diagnosed Disease

Nitin Jain, MD, on B-Cell ALL: Expert Perspective on Key CAR T-Cell Treatment Advances

Steven M. Horwitz, MD, on T-Cell Lymphoma: Update on Allogeneic Hematopoietic Transplant

Tycel J. Phillips, MD, on Marginal Zone Lymphoma: Efficacy and Safety of Parsaclisib

Steven M. Horwitz, MD, on PTCL: Update on Efficacy of Duvelisib Dose Optimization

Christian Marinaccio, PhD Candidate: Genetic Driver May Play a Role in Progression of Myeloproliferative Neoplasms to AML

Lena E. Winestone, MD, MSHP, on Health-Care Disparities in Hematologic Cancers: Real-World Data

Sara Zarnegar-Lumley, MD, on AML: Prognostic Effects of IDH Mutations


Quantitative Imaging Workshop XVII

Daniel G. Petereit, MD, on Disparities in Lung Cancer Care for Northern Plains American Indians

Fred R. Hirsch, MD, PhD, on Early-Stage Lung Cancer: Targeted Treatment and Screening

David Yankelevitz, MD, on Early-Stage Lung Cancer: Renewed Interest in Combined-Modality Treatment

James L. Mulshine, MD, on Meeting Highlights: Advancing Quantitative Low-Dose CT Imaging in Thoracic Disease

Mary Pasquinelli, DNP, APRN, FNP-BC, on Addressing Lung Cancer Care Equity in Vulnerable Communities


2020 ASTRO Annual Meeting

Neha Vapiwala, MD, on Prostate Cancer: Imaging and the Decision to Treat With Radiation

Arjun Sahgal, MD, on Reducing the Pain of Spinal Metastases: SBRT vs Palliative Radiotherapy

Juliane Hörner-Rieber, MD, on Breast Cancer: Boosting Intensity-Modulated and Conventional Radiotherapies

Paul Sargos, MD, on Prostate Cancer: Adjuvant or Early Salvage Radiotherapy Plus Androgen Deprivation

Youssef Zeidan, MD, PhD, on HER2-Positive Breast Cancer: Deintensifying Radiation Therapy

Cynthia Menard, MD, on Prostate Cancer: PSMA PET- and CT-Guided Intensification of Radiotherapy

Daniel E. Spratt, MD, on Prostate Cancer: Short-Term Adjuvant vs Neoadjuvant Hormone Therapy

Daniel E. Spratt, MD, on Prostate Cancer: Relugolix vs Leuprolide

Alphonse G. Taghian, MD, PhD, on Irradiation for Breast Cancer: Defining the Optimal Dose

Vinai Gondi, MD, on Glioblastoma: Dose Intensification, IMRT, Standard Radiotherapy, and Temozolomide

Jing Li, MD, PhD, on Brain Metastases: Stereotactic Radiosurgery vs Whole-Brain Radiation Therapy

Justin Oh, MD, on Prostate Cancer: Brachytherapy vs External-Beam Radiation Therapy

Jeff M. Michalski, MD, MBA, on Medulloblastoma and Radiation Treatment in Pediatric Patients

Linda G.W. Kerkmeijer, MD, PhD, on Prostate Cancer: Adding a Focal Boost to External-Beam Radiotherapy


2020 ASCO Quality Care Symposium

Melissa K. Accordino, MD, on Breast Cancer Care Delivery: Impact of the COVID-19 Pandemic

Veena Shankaran, MD, on Colorectal Cancer: Cumulative Financial Hardship of Treatment

Joseph M. Unger, PhD, on Patient Interest in Clinical Trial Enrollment: A New Analysis

Katherine Enright, MD, MPH, on Improving the Quality of Oral Cancer Drug Delivery

Marie A. Flannery, PhD, and Eva Culakova, PhD, on Managing Symptoms in Older Adults With Advanced Cancer

Anne M. Barry-Weers, RN, on Decreasing Hospitalizations for Patients Receiving IV Chemotherapy

Cardinale B. Smith, MD, PhD, on Telehealth Disparities During the COVID-19 Pandemic

Cardinale B. Smith, MD, PhD, on Redesigning Care Coordination From the Patient’s Perspective

James D. Murphy, MD, on Opioid Use Among Patients With Cancer


ESMO Virtual Congress 2020

Masahiro Tsuboi, MD, on NSCLC: Adjuvant Osimertinib in EGFR-Mutated Disease

Toni K. Choueiri, MD, on RCC: Nivolumab Plus Cabozantinib vs Sunitinib in First-Line Treatment

Mansoor Raza Mirza, MD, on Endometrial Cancer: Palbociclib Plus Letrozole in ER-Positive Disease

Andreas Schneeweiss, MD, on Breast Cancer: Comparing Neoadjuvant Chemotherapy With Paclitaxel, Doxorubicin, and Carboplatin

Erika P. Hamilton, MD, on Breast Cancer: Abemaciclib With or Without Tamoxifen in HR-Positive, HER2-Negative Metastatic Disease

Ezra E.W. Cohen, MD, on Head and Neck Cancer: Avelumab and Chemoradiotherapy in Locally Advanced Disease

David S. Hong, MD, on NSCLC: Durability of Clinical Benefit and Biomarkers in Patients Treated With Sotorasib

Sumanta K. Pal, MD, on Renal Cell Carcinoma: Cabozantinib Plus Atezolizumab as First-Line Therapy

Nicholas D. James, PhD, MBBS, on Prostate Cancer: Abiraterone Acetate Plus Prednisolone for Hormone-Naive Disease

Stephen R.D. Johnston, MD, PhD, on Early Breast Cancer: Abemaciclib in High-Risk Disease

Thierry Andre, MD, on Colorectal Cancer: Health-Related Quality of Life With Pembrolizumab vs Chemotherapy

Paolo A. Ascierto, MD, on Melanoma: Sequencing Targeted Treatments and Immunotherapy

Benjamin Besse, MD, PhD, on NSCLC: Neoadjuvant Atezolizumab for Resectable Disease

Cécile Le Pechoux, MD, on NSCLC: Comparing Postoperative Radiotherapy With No Radiotherapy

Erica L. Mayer, MD, MPH, on Early Breast Cancer: Palbociclib With Endocrine Therapy vs Endocrine Therapy Alone

Aditya Bardia, MD, MPH, on Triple-Negative Breast Cancer: Sacituzumab Govitecan vs Treatment of Physician’s Choice

Alexander M. Eggermont, MD, PhD, on Melanoma: Pembrolizumab vs Placebo After Complete Resection

Lisa A. Carey, MD, on Triple-Negative Breast Cancer: Paclitaxel, Nab-paclitaxel, and Atezolizumab in IMpassion Trials

Monika K. Krzyzanowska, MD, MPH, on Early-Stage Breast Cancer: Ambulatory Toxicity Management in the AToM Study

Jeffrey S. Weber, MD, PhD, on Melanoma: Adjuvant Nivolumab vs Ipilimumab

Andreas du Bois, MD, PhD, on Ovarian Cancer: Niraparib, Trabectedin Plus Doxorubicin, Platinum, and Carboplatin


IASLC World Conference on Lung Cancer

Paul Baas, MD, PhD, on Mesothelioma: First-Line Nivolumab Plus Ipilimumab vs Chemotherapy

Misako Nagasaka, MD, on NSCLC: Sintilimab, Pemetrexed, and Platinum as First-Line Therapy

Leora Horn, MD, on NSCLC: Ensartinib vs Crizotinib in ALK–Positive Disease

Marina C. Garassino, MD, on COVID-19 and Thoracic Malignancies: TERAVOLT Registry


ASCO20 Virtual Education Program

Matti S. Aapro, MD, on Curing Sarcomas: An Expert Review


AACR Virtual Meeting: COVID-19 and Cancer 2020

Arthur L. Caplan, PhD, on Ethics, Cancer, and COVID-19

Karen E. Knudsen, MBA, PhD, on the Challenges of Using Telehealth in Cancer Care

Catherine H. Marshall, MD, MPH, on Promoting Recovery From COVID-19 Infection With Endocrine Therapy

Antoni Ribas, MD, PhD, on AACR Virtual Meeting: COVID-19 and Cancer Highlights

Nancy E. Davidson, MD, on Bringing Patients With Cancer Back to the Clinic During the COVID-19 Pandemic

Jessica Y. Islam, PhD, MPH, on COVID-19 Preventive Behaviors Among Cancer Survivors

Gabriella Pravettoni, PhD, on COVID-19 and Cancer: Psychological Effects on Patients and Oncologists

Dafna Bar-Sagi, PhD, on COVID-19: How Cancer Researchers Can Help Address the Challenges


First International Summit on Interventional Pharmacoeconomics

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Clifford A. Hudis, MD, and Allen S. Lichter, MD, on Oncology Drug Pricing in the United States: What You Need to Know

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Welcome and Introduction to Vi3C

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Opening Session Panel Discussion

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Varsha Gandhi, PhD, on Ibrutinib

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Peter Clark, MA, MD, FRCP: A Payer Perspective

Amit Sanyal, MD: A Clinician’s Perspective

Matthew Seymour, MD: A Clinical Trialist’s Perspective

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Opportunities to Optimize Cancer Policies Panel Discussion

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

David A. Hyman, MD, JD, on Inclusive Shared Savings

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Deborah Collyar: What's In It for Patients?

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Advertisement

Advertisement



Jun
23
Today In Oncology
Adjuvant Metronomic Capecitabine for Locoregionally Advanced Nasopharyngeal Carcinoma
FDA Pipeline Priority Reviews in Multiple Myeloma, Cervical Cancer, Neutropenia, and Myelofibrosis
Phase II Study of Naratuximab Emtansine Plus Rituximab in Diffuse Large B-Cell Lymphoma
Overall Survival With the Addition of Ixazomib to Lenalidomide/Dexamethasone in Relapsed or Refractory Multiple Myeloma
Reduced-Dose and Reduced-Volume Radiotherapy Plus Chemotherapy in Newly Diagnosed Patients With Average-Risk Medulloblastoma
View More 
Advertisement
© 2021 HSP News Service, L.L.C.
Designed by Harborside